IN THE CLAIMS:

Please amend the claims as shown in the following listing of claims:

1.-17. (canceled)

18. (previously presented) A process for preparing crystalline solid famciclovir characterized by a XRD pattern with peaks at 15.5 and 15.9 ± 0.2 deg. 2θ, comprising the steps of:

a) triturating an anhydrous famciclovir form in an organic solvent selected from the group consisting of isopropyl alcohol and acetonitrile; and

b) isolating the crystalline solid famciclovir characterized by a XRD pattern with peaks at 15.5 and 15.9 ± 0.2 deg. 2θ.

19.-34. (canceled)

35. (previously presented) A process of preparing a crystalline solid famciclovir monohydrate, comprising the steps of:

a) providing a solution of famciclovir in an ethanol/water mixture, DMF/water mixture, DMA/water mixture, acetonitrile/water mixture, methanol/water mixture, tetrahydrofuran/water mixture, and/or isopropyl alcohol/water mixture; and

b) cooling the solution; and

c) isolating the crystalline solid famciclovir monohydrate.

36.-52. (canceled)

53. (previously presented) Crystalline solid famciclovir methanol solvate, characterized by a XRD pattern with peaks at 6.6 and 13.0 ± 0.2 deg. 2θ.

54. (previously presented) The crystalline solid famciclovir solvate of claim 53, further characterized by the XRD pattern having peaks at 15.9, 16.7, 18.4, 19.6, 24.5, 25.0 and 26.2 ± 0.2 deg. 2θ.

55. (previously presented) The crystalline solid famciclovir solvate of claim 54, wherein the XRD pattern is as substantially depicted in Fig. 3.

56. (previously presented) The crystalline solid famciclovir solvate of claim 53, containing less than about 5% wt of another famciclovir crystalline form.

57. (previously presented) Crystalline solid famciclovir ethanol solvate, characterized by a XRD pattern having peaks at 6.6 and 13.0 ± 0.2 deg. 2θ.

58. (previously presented) Crystalline solid famciclovir methanol solvate.

59. (previously presented) Crystalline solid famciclovir ethanol solvate.

60. (previously presented) A process for preparing crystalline solid famciclovir, characterized by a XRD pattern with peaks at 15.5 and 15.9 ± 0.2 deg. 2θ, comprising the steps of:

a) heating crystalline solid famciclovir methanol or ethanol solvate, characterized by a XRD pattern with peaks at 6.6 and 13.0 ± 0.2 deg. 2θ, to about 40° C to about 90° C; and
b) isolating the crystalline solid famciclovir characterized by a XRD pattern with peaks at 15.5 and 15.9 ± 0.2 deg. 2θ.

61. (previously presented) The process of claim 60, wherein the heating of the crystalline solid famciclovir methanol or ethanol solvate is performed at a temperature of about 60° C to about 70° C.

62. (currently amended) A process for preparing crystalline solid famciclovir characterized by a XRD pattern with peaks at 15.5 and 15.9 ± 0.2 deg. 2θ, comprising the steps of:

a) heating famciclovir monohydrate to about <u>60° C to about 70° C</u> ~~40° C to about 80° C~~; and
b) isolating the crystalline solid famciclovir characterized by a XRD pattern with peaks at 15.5 and 15.9 ± 0.2 deg. 2θ.

63. (previously presented) The process of claim 62, wherein step a) is performed by heating a mixture of the famciclovir monohydrate and crystalline solid famciclovir characterized by a XRD pattern with peaks at 15.5 and 15.9 ± 0.2 deg. 2θ.

64. (cancelled)

65. (previously presented) A process for preparing crystalline solid famciclovir, characterized by a XRD pattern with peaks at 15.5 and 15.9 ± 0.2 deg. 2θ, comprising the steps of:

a) heating crystalline solid famciclovir characterized by a XRD pattern with peaks at 16.2 and 16.4 ± 0.2 deg. 2θ, to about 40° C to about 90° C; and
b) isolating the crystalline solid famciclovir characterized by a XRD pattern with peaks at 15.5 and 15.9 ± 0.2 deg. 2θ.

66. (previously presented) The process of any one of claims 60, 62 and 65, wherein the isolated crystalline solid famciclovir contains less than about 5% wt of other famciclovir crystalline forms.

67. (previously presented) The process of any one of claims 60, 62 and 65, wherein the isolated crystalline solid famciclovir contains less than about 5% wt of crystalline famciclovir characterized by a XRD pattern with peaks at 16.2 and 16.4 ± 0.2 deg. 2θ.

68. (previously presented) The process of claim 66, wherein the isolated crystalline solid famciclovir contains less than about 1% wt of other famciclovir crystalline forms.

69. (previously presented) The process of claim 68, wherein the isolated crystalline solid famciclovir contains less than about 1% wt of crystalline famciclovir characterized by a XRD pattern with peaks at 16.2 and 16.4 ± 0.2 deg. 2θ.

70. (previously presented) A process for preparing a mixture of crystalline solid famciclovir characterized by a XRD pattern with peaks at 16.2 and 16.4 ± 0.2 deg. 2θ, and

crystalline solid famciclvir characterized by a XRD pattern with peaks at 15.5 and 15.9 ± 0.2 deg. 2θ, comprising the steps of:

a) providing a solution of famciclovir in an organic solvent selected from the group consisting of chloroform, diethyl ether/dichloromethane mixture, tetrahydrofuran, acetonitrile/toluene mixture and dimethylacetamide,
b) cooling the solution, and
c) isolating the mixture of the crystalline solid famciclovir characterized by a XRD pattern with peaks at 16.2 and 16.4 ± 0.2 deg. 2θ and the crystalline solid famciclovir characterized by a XRD pattern with peaks at 15.5 and 15.9 ± 0.2 deg. 2θ.

71. (previously presented) A process for preparing the crystalline solid famciclovir methanol solvate of claim 53, comprising the steps of:

a) triturating an anhydrous famciclovir in methanol; and
b) isolating the crystalline solid famciclovir methanol solvate.

72. (previously presented) A process of preparing a mixture of the crystalline solid famciclovir ethanol solvate of claim 57 and crystalline solid famciclovir characterized by a XRD pattern with peaks at 15.5 and 15.9 ± 0.2 deg. 2θ and containing less than about 5% wt of another famciclovir crystalline form, comprising the steps of:

a) triturating an anhydrous famciclovir in ethanol; and
b) isolating the mixture of the crystalline solid famciclovir ethanol solvate of claim 57 and the crystalline solid famciclovir characterized by a XRD pattern with peaks at 15.5 and 15.9 ± 0.2 deg. 2θ.

73. (previously presented) A process for preparing a mixture of the crystalline solid famciclovir ethanol solvate of claim 57 and crystalline solid famciclovir monohydrate, comprising the steps of:

a) triturating anhydrous famciclovir in an ethanol/water mixture; and
b) isolating the mixture of the crystalline solid famciclovir ethanol solvate and crystalline solid famciclovir monohydrate.

74. (currently amended) A solid pharmaceutical composition comprising a crystalline solid famciclovir ~~methanol or~~ ethanol solvate of claim ~~53 or~~ 57 and a pharmaceutically-acceptable excipient, wherein the crystalline solid famciclovir ~~methanol or~~ ethanol solvate contains less than about 5% wt of another famciclovir crystalline form.

75. (currently amended) The solid pharmaceutical composition of claim 74, wherein the crystalline solid famciclovir ~~methanol or~~ ethanol solvate contains less than about 1% wt of another famciclovir crystalline form.

76. (previously presented) A method of treating a human in need of treatment with famciclovir administering to the human the pharmaceutical composition of any one of claims 74-75.

77. (previously presented) The crystalline solid famciclovir ethanol solvate of claim 57, further characterized by the XRD pattern having peaks at 15.9, 16.7, 18.4, 19.6, 24.5, 25.0 and 26.2 ± 0.2 deg. 2θ.

78. (previously presented) The crystalline solid famciclovir methanol solvate of claim 56, containing less than about 1% wt of another famciclovir crystalline form.

79. (previously presented) A process for preparing crystalline solid famciclovir characterized by a XRD pattern with peaks at 15.5 and 15.9 ± 0.2 deg. 2θ and containing less than about 5% wt of another famciclovir crystalline form, comprising the steps of:

a) providing a solution of famciclovir in an organic solvent selected from the group consisting of dichloromethane, chloroform, acetonitrile, acetone, THF, diethyl ether/dichloromethane mixture, dichloromethane/toluene mixture, ethylacetate/toluene mixture, acetonitrile/toluene mixture and dimethylacetamide,

b) cooling the solution, and

c) isolating the crystalline solid famciclovir characterized by a XRD pattern with peaks at 15.5 and 15.9 ± 0.2 deg. 2θ.

80. (previously presented) The process of claim 18, wherein the isolated crystalline solid famciclovir contains less than about 5% wt of other famciclovir crystalline forms.

81. (previously presented) The process of claim 18, wherein the isolated crystalline solid famciclovir contains less than about 5% wt of crystalline famciclovir characterized by a XRD pattern with peaks at 16.2 and 16.4 ± 0.2 deg. 2θ.

82. (previously presented) The process of claim 18, wherein the isolated crystalline solid famciclovir contains less than about 1% wt of other famciclovir crystalline forms.

83. (previously presented) The process of claim 18, wherein the isolated crystalline solid famciclovir contains less than about 1% wt of crystalline famciclovir characterized by a XRD pattern with peaks at 16.2 and 16.4 ± 0.2 deg. 2θ.

84. (previously presented) A process for preparing crystalline solid famciclovir characterized by a XRD pattern with peaks at 15.5 and 15.9 ± 0.2 deg. 2θ, comprising the steps of:

a) providing a solution of famciclovir in an organic solvent selected from the group consisting of dichloromethane, chloroform, acetonitrile, acetone, THF, diethyl ether/dichloromethane mixture, dichloromethane/toluene mixture, ethylacetate/toluene mixture, acetonitrile/toluene mixture and dimethylacetamide,

b) cooling the solution, and

c) isolating the crystalline solid famciclovir characterized by a XRD pattern with peaks at 15.5 and 15.9 ± 0.2 deg. 2θ.

85. (previously presented) A process for preparing crystalline solid famciclovir characterized by a XRD pattern with peaks at 16.2 and 16.4 ± 0.2 deg. 2θ, comprising the steps of:

a) providing a solution of famciclovir in ethanol,

b) cooling the solution whereby the crystalline solid famciclovir characterized by a XRD pattern with peaks at 16.2 and 16.4 ± 0.2 deg. 2θ crystallizes, and

c) isolating the crystalline solid famciclovir.